CAS: 138274-14-3; 5-(Benzyloxy)-2-Chloropyrimidine

相似化合物

91183-17-4 42783-58-4 1206181-50-1

上下游产品

benzyl bromide 2-chloropyrimidine-5-ol benzyl chloride 1-(5-Benzyloxy-2-pyrimidinyl)piperazine butyl>-2,3-bicycloheptanedicarboximide(1R*,2S*,3R*,4S*)-N-4-4-(5-Benzyloxy-2-pyrimidinyl)-1-piperazinylbutyl-2,3-bicyclo2.2.1heptanedicarboximide 5-[5-(benzyloxy)pyrimidin-2-ylamino]-2-fluoro-benzonitrile [(3R,4S)-1-(5-benzyloxypyrimidin-2-yl)-4-(2,4,5-trifluorophenyl)pyrrolidin-3-yl]carbamic acid tert-butyl ester

📜溴甲苯,2-氯-5-羟基嘧啶置于potassium Carbonate体系中,用 N,N-二甲基甲酰胺 用作溶剂,化学反应 1.0H,以89.7%的收率获得2-氯-5-(苯甲氧基)嘧啶
参考文献:N-取代的环状酰亚胺(1R *,2S *,3R *,4S *)-N-[4-[4-(2-嘧啶基)-1-哌嗪基]丁基]-2,3-双环的合成及抗焦虑活性[2.2.1]庚烷二甲酰亚胺(tandospirone)和相关化合物.
标题:N-取代的环状酰亚胺(1R *,2S *,3R *,4S *)-N-[4-[4-(2-嘧啶基)-1-哌嗪基]丁基]-2,3-双环的合成及抗焦虑活性[2.2.1]庚烷二甲酰亚胺(tandospirone)和相关化合物.
摘要:合成了一系列带有ω-(4-芳基和4-杂芳基-1-哌嗪基)烷基的环状酰亚胺,并在体内测试其抗焦虑活性.还检查了这些化合物的体外结合亲和力的5-Ht1A受体位点.讨论了这些系列中的构效关系.这些化合物之一,(1R *,2S *,-3R *,4S *)-N-[4-[4-(4-嘧啶基)-1-哌嗪基]丁基]-2,3-双环[2.2.1已发现]庚烷二甲酰亚胺(1:Tandospirone)与丁螺环酮具有相同的抗焦虑活性,并且比丁螺环酮和地西epa具有更高的选择性.Tandospirone(1)目前正在作为一种选择性抗焦虑药进行临床评估.
Doi:10.1248/cpb.39.2288

专利信息

专利号:US-9795613-B2
优先权日:2014-12-10
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL; GLYNN DANIEL; MILLS MARK
权利人:CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.

专利号:US-9187522-B2
优先权日:2011-12-12
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC
摘要:The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.

专利号:US-9598430-B2
优先权日:2013-06-11
标 题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC; CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.